Pfizer CEO Albert Bourla tests positive for COVID-19 for second time in less than 2 months
Bourla says he is symptom-free after second positive COVID-19 test
FOX Business Flash top headlines for September 23
Check out what's clicking on FoxBusiness.com
Pfizer Chairman and CEO Albert Bourla on Saturday said that has tested positive for COVID-19 for the second time in less than two months.
Bourla, who heads the company that helped to create the widely used Pfizer-BioNTech coronavirus vaccine, said he was feeling well and symptom-free.
"I’ve not had the new bivalent booster yet, as I was following CDC guidelines to wait 3 months since my previous COVID case, which was back in mid-August," Bourla said.
"While we’ve made great progress, the virus is still with us," Bourla added.
Bourla previously announced on Aug. 14 that he tested positive for the virus and was experiencing mild symptoms.
PFIZER TO SUPPLY UP TO 6 MILLION COURSES OF COVID-19 TREATMENT FOR LOWER-INCOME COUNTRIES
NEW YORK, NY - NOVEMBER 9: Albert Bourla attends The New York Times DealBook Online Summit on November 9, 2021 in New York City. (Photo by Ryan Muir/Getty Images via The New York Times) (Ryan Muir/Getty Images via The New York Times / Getty Images)
Late last month, the U.S. Food and Drug Administration (FDA) announced that it has authorized updated coronavirus booster shots targeting the highly-contagious omicron variant.
| Ticker | Security | Last | Change | Change % |
|---|---|---|---|---|
| PFE | PFIZER INC. | 24.80 | -1.22 | -4.70% |
"As we head into fall and begin to spend more time indoors, we strongly encourage anyone who is eligible to consider receiving a booster dose with a bivalent COVID-19 vaccine to provide better protection against currently circulating variants," FDA Commissioner Robert Califf said in a statement at the time.
GET FOX BUSINESS ON THE GO BY CLICKING HERE
The shots, which the FDA is referring to as "updated boosters," contain "two messenger RNA (mRNA) components of SARS-CoV-2 virus, one of the original strain of SARS-CoV-2 and the other one in common between the BA.4 and BA.5 lineages of the omicron variant of SARS-CoV-2."